The FDA’s decision to remove menopause drug warnings without expert review or transparency raises serious concerns about public safety and regulatory accountability.
AI-generated summary. Check the original reporting for context and accuracy.
This is the available feed excerpt, which may be shortened or in the publisher’s original language.
Some experts express concern about ‘lack of transparency’ as agency removes warnings on three estrogen patchesThree more patches for treating menopause will no longer carry black-box warnings about cardiovascular disease, breast cancer and dementia, officials at the US Food and Drug Administration (FDA) said on Friday.The FDA did not convene an advisory committee and offered few details on the scientific basis for the decision in the press briefing. The news follows the removal of black-box warnings from six menopause treatments in February, as patients across the US struggle with shortages of the patches. Continue reading...
An automated sorting aid based on source trust, keywords, and entities, on a scale of 1–12. High: 9–12; medium: 6–8; low: 1–5. It does not measure urgency, verify reporting, or indicate editorial endorsement.
Police deployed during a standoff over Poland's top court after the government suspended two senior justices and moved to criminally charge them.
Police deployment during a standoff over Poland's top court highlights escalating political conflict after the government suspended two senior justices and pursued criminal charges against them.
The closure of Novaya Gazeta, a leading independent Russian newspaper, signals a severe crackdown on press freedom and the elimination of critical voices in Russia.